



10/753,665

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Dennis A. Carson et al.	Examiner:	Frederick F. Krass
Serial No.:	10/753,665	Group Art Unit:	1614
Filed:	January 08, 2004	Docket:	103.014US3
Title:	USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

The attached documents were discovered as a result of a Search Report in Applicants' corresponding foreign patent application. Enclosed for the Examiner's information is a copy of the cited documents and the Search Report.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

Applicants note that the document WO 02/12188 A2 was cited in the Supplemental Information Disclosure Statement mailed on November 16, 2004. Enclosed are copies of all documents from the PCT not previously submitted in this matter.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/753,665

Filing Date: January 08, 2004

Title: USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Page 2

Dkt: 103.014US3

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

DENNIS A. CARSON ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6968

Date June 15, 2005

By William F. Prout
William F. Prout
Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 5th day of May, 2005.

Dawn M. Boyle
Name

Dawn M. Boyle
Signature



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/753,665
Filing Date	January 8, 2004
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Krass, Frederick

Sheet 1 of 1

Attorney Docket No: 103.014US3

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-4,041,169	08/09/1977	Demerson, Christopher A., et al.	10/28/1976
	US-4,179,503	12/18/1979	Asselin, Andre A., et al.	05/08/1978
	US-6,110,955	08/29/2000	Nudelman, A. , et al.	03/11/1997

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	CA-1299577	04/28/1992	Guindon, Y., et al.	
	GB-1436893	05/26/1976	Aktiengesellschaft, S., et al.	
	WO-02/02125A1	01/10/2002	Tait, Russell , et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		<u>Drug Facts and Comparisons, 1995 Edition, Wolters Kluwer Co.,(1995),2775-2789</u>	
		"International Search Report for PCT Application No. PCT/US2004/032185" (Attorney Docket No. 31059-701601), (April 20, 2005), 11 pgs.	
		BRENNA, ELISABETTA , et al., "New Enzymatic and Chemical Approaches to Enantiopur Etodolac", <u>Tetrahedron, Vol. 53, No. 52, (1997),17769-17780</u>	
		KOLLURI, S. K., et al., "The R-Enantiomer of the Nonsteroidal Antiinflammatory Drug Etodolac Binds Retinoid X Receptor and Induces Tumor-Selective Apoptosis", <u>Proc. Natl. Acad. Sci. USA., 102(7), (2005), 2525-2530</u>	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached